Medical XpressMillions of US Birth Records Uncover an Autism Risk Surge Tied to Common Drugs Taken During Pregnancy

ℹ️ Observational Association Only Evidence
A retrospective analysis of 6.14 million maternal-child records from Epic Cosmos found prenatal prescription of 14 sterol biosynthesis–inhibiting medications was associated with higher ASD diagnosis rates. The grouping spans antidepressants, antipsychotics, anxiolytics, beta-blockers, and statins.

Clinical Considerations

• Maternal SBIM exposure was associated with a 1.47-fold higher risk of ASD diagnosis, with dose-dependent escalation to 2.33-fold when four or more SBIMs were co-prescribed.
• SBIM use during pregnancy rose from 4.3% in 2014 to 16.8% in 2023, reflecting broader prescribing trends in reproductive-age patients.
• The mechanistic hypothesis centers on fetal brain cholesterol synthesis, which begins around 19-20 weeks gestation and is disrupted in genetic syndromes like Smith-Lemli-Opitz.
• Findings did not establish causality and are vulnerable to confounding by indication, as underlying maternal conditions independently influence neurodevelopmental risk.

Practice Applications

• Recognize these findings as hypothesis-generating, not as a basis for altering prescribing in pregnancy.
• Reassure pregnant patients that authors explicitly advise against discontinuing or modifying medications without medical supervision.
• Interpret the dose-response signal cautiously given uncontrolled confounding from underlying maternal indications.
• Monitor forthcoming mechanistic research and any society guidance on sterol pathway considerations in pregnancy prescribing.

More in ASD